Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Proteasome inhibitors in cancer therapy: lessons from the first decade.

Orlowski RZ, Kuhn DJ.

Clin Cancer Res. 2008 Mar 15;14(6):1649-57. doi: 10.1158/1078-0432.CCR-07-2218. Review.

2.

The potential of proteasome inhibitors in cancer therapy.

Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, Terpos E, Sezer O.

Expert Opin Investig Drugs. 2008 Jun;17(6):879-95. doi: 10.1517/13543784.17.6.879 . Review.

PMID:
18491989
3.

Proteasome inhibitors in cancer therapy.

Testa U.

Curr Drug Targets. 2009 Oct;10(10):968-81. Review.

PMID:
19548862
4.
5.

Proteasome inhibitors: a therapeutic strategy for haematological malignancy.

Crawford LJ, Walker B, Irvine AE.

Front Biosci. 2008 May 1;13:4285-96. Review.

PMID:
18508511
6.

Proteasome inhibition as a new therapeutic principle in hematological malignancies.

Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC.

Curr Drug Targets. 2006 Oct;7(10):1341-7. Review.

PMID:
17073596
7.

Development of proteasome inhibitors in oncology and autoimmune diseases.

Bennett MK, Kirk CJ.

Curr Opin Drug Discov Devel. 2008 Sep;11(5):616-25. Review.

PMID:
18729013
8.

Proteasome as an emerging therapeutic target in cancer.

Zavrski I, Kleeberg L, Kaiser M, Fleissner C, Heider U, Sterz J, Jakob C, Sezer O.

Curr Pharm Des. 2007;13(5):471-85. Review.

PMID:
17348844
9.

Targeting the ubiquitin-proteasome pathway in cancer therapy.

Ishii Y, Waxman S, Germain D.

Anticancer Agents Med Chem. 2007 May;7(3):359-65. Review.

PMID:
17504161
10.

Targeting the proteasome as a therapeutic strategy against haematological malignancies.

Orlowski RZ, Zeger EL.

Expert Opin Investig Drugs. 2006 Feb;15(2):117-30. Review.

PMID:
16433592
11.

The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.

Ruggeri B, Miknyoczki S, Dorsey B, Hui AM.

Adv Pharmacol. 2009;57:91-135. doi: 10.1016/S1054-3589(08)57003-7. Epub 2009 Nov 27. Review.

PMID:
20230760
12.

Bortezomib in combination with other therapies for the treatment of multiple myeloma.

Orlowski RZ.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S16-20. Review.

PMID:
19791424
13.
14.

The role of proteasome in malignant diseases.

Moran E, Nencioni A.

J BUON. 2007 Sep;12 Suppl 1:S95-9. Review.

PMID:
17935285
15.

Investigational treatments for multiple myeloma.

Bringhen S, Avonto I, Magarotto V, Boccadoro M, Palumbo A.

Expert Opin Investig Drugs. 2006 Dec;15(12):1565-82. Review.

PMID:
17107282
16.

[Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].

Tobinai K.

Rinsho Ketsueki. 2007 Jun;48(6):451-7. Review. Japanese. No abstract available.

PMID:
17633092
17.

Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.

Genin E, Reboud-Ravaux M, Vidal J.

Curr Top Med Chem. 2010;10(3):232-56. Review.

PMID:
20166955
18.

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.

Dick LR, Fleming PE.

Drug Discov Today. 2010 Mar;15(5-6):243-9. doi: 10.1016/j.drudis.2010.01.008. Epub 2010 Jan 29. Review.

PMID:
20116451
19.

Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).

Kuhn DJ, Orlowski RZ, Bjorklund CC.

Curr Cancer Drug Targets. 2011 Mar;11(3):285-95. Review.

PMID:
21247387
20.

The therapeutic potential of the proteasome in leukaemia.

McCloskey SM, McMullin MF, Walker B, Irvine AE.

Hematol Oncol. 2008 Jun;26(2):73-81. doi: 10.1002/hon.848. Review.

PMID:
18324639

Supplemental Content

Support Center